Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.33 |
| ▸ | MAOB | P27338 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 2/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | ATM | Q13315 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | PKM | P14618 | 1/20 | 0.30 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18229679 | 1.00 | ALDH1A1 (0.33) | ALDH1A1MAOBTSHRSMN1; SMN2LMNA | |
| SCHEMBL18235805 | 0.79 | PPARA (0.32) | — | |
| SCHEMBL20156637 | 0.77 | — | — | |
| SCHEMBL20150669 | 0.77 | — | — | |
| SCHEMBL24192697 | 0.74 | ALDH1A1 (0.35) | ALDH1A1MAOBTSHR | |
| SCHEMBL1463760 | 0.74 | ALDH1A1 (0.35) | ALDH1A1MAOBTSHR | |
| SCHEMBL1463759 | 0.74 | ALDH1A1 (0.35) | ALDH1A1MAOBTSHR | |
| SCHEMBL1464523 | 0.74 | ALDH1A1 (0.35) | ALDH1A1MAOBTSHR | |
| SCHEMBL1464529 | 0.74 | ALDH1A1 (0.35) | ALDH1A1MAOBTSHR | |
| SCHEMBL18229672 | 0.73 | PKM (0.30) | ALDH1A1NPC1RAB9APKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10597401-B2 | Methods and intermediates for the preparation of omacetaxine and cephalotaxine derivatives thereof | ALBANY MOLECULAR RESEARCH, INC. (US) | 2020-03-24 | — | — | US | disclosed |
| US-20180134724-A1 | METHODS AND INTERMEDIATES FOR THE PREPARATION OF OMACETAXINE AND CEPHALOTAXINE DERIVATIVES THEREOF | CURIA BUFFALO R&D, LLC | 2018-05-17 | — | — | US | disclosed |
| WO-2016182850-A1 | METHODS AND INTERMEDIATES FOR THE PREPARATION OF OMACETAXINE AND CEPHALOTAXINE DERIVATIVES THEREOF | ALBANY MOLECULAR RESEARCH, INC. (US) | 2016-11-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10597401-B2 | Methods and intermediates for the preparation of omacetaxine and cephalotaxine derivatives thereof | MAOB, MAOA, NISCH | ALDH1A1 418/4885MAOB 1/4885TSHR 3247/4885 |
| US-20180134724-A1 | METHODS AND INTERMEDIATES FOR THE PREPARATION OF OMACETAXINE AND CEPHALOTAXINE DERIVATIVES THEREOF | MAOB, MAOA, NISCH | ALDH1A1 418/4885MAOB 1/4885TSHR 3247/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.